Literature DB >> 1700536

Decay-accelerating factor in the cardiomyocytes of normal individuals and patients with myocardial infarction.

A Zimmermann1, H Gerber, V Nussenzweig, H Isliker.   

Abstract

The presence of decay-accelerating factor (DAF) was clearly demonstrated on the surface of normal cardiomyocytes. In patients who had died of myocardial infarction (MI) cardiomyocytes displayed different appearances: outside the ischaemically damaged region the myocytes showed no significant variations in DAF expression when compared with controls without MI. Within myocardial zones damaged by ischaemia, however, apparently normal myocytes showed large gaps in surface staining of DAF or formed clusters which were entirely devoid of reactivity with anti-DAF antibodies. The number of DAF-deficient myocytes increased with the extent of necrosis and also with the number of days between onset of MI and death. Even though injury to myocytes is to a large extent related to anoxia and to the presence of free oxygen radicals, the complement system also appears to be involved; DAF may have protective functions against complement-mediated injury. We speculate that phospholipase may be involved in the removal of DAF from the cardiomyocyte surface.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1700536     DOI: 10.1007/bf01605780

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  44 in total

1.  Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.

Authors:  M C Peitsch; T J Kovacsovics; J Tschopp; H Isliker
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

2.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

3.  Phorbol esters increase synthesis of decay-accelerating factor, a phosphatidylinositol-anchored surface protein, in human endothelial cells.

Authors:  R W Bryant; C A Granzow; M I Siegel; R W Egan; M M Billah
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

4.  Synthesis of aberrant decay-accelerating factor proteins by affected paroxysmal nocturnal hemoglobinuria leukocytes.

Authors:  D J Carothers; S V Hazra; S W Andreson; M E Medof
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

5.  Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions.

Authors:  P S Seifert; G K Hansson
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

6.  Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase.

Authors:  S R Jolly; W J Kane; M B Bailie; G D Abrams; B R Lucchesi
Journal:  Circ Res       Date:  1984-03       Impact factor: 17.367

7.  The Thy-1 antigen exhibits rapid lateral diffusion in the plasma membrane of rodent lymphoid cells and fibroblasts.

Authors:  A Ishihara; Y Hou; K Jacobson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

8.  Antibody-independent activation of the complement system by mitochondria is mediated by cardiolipin.

Authors:  M C Peitsch; J Tschopp; A Kress; H Isliker
Journal:  Biochem J       Date:  1988-01-15       Impact factor: 3.857

9.  Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.

Authors:  M A Davitz; M G Low; V Nussenzweig
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

10.  Decay-accelerating factor is present on cultured human umbilical vein endothelial cells.

Authors:  A S Asch; T Kinoshita; E A Jaffe; V Nussenzweig
Journal:  J Exp Med       Date:  1986-01-01       Impact factor: 14.307

View more
  6 in total

1.  Membrane attack complex of complement and 20 kDa homologous restriction factor (CD59) in myocardial infarction.

Authors:  T Tada; H Okada; N Okada; H Tateyama; H Suzuki; Y Takahashi; T Eimoto
Journal:  Virchows Arch       Date:  1997-04       Impact factor: 4.064

2.  Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment.

Authors:  D R Shafren; R C Bates; M V Agrez; R L Herd; G F Burns; R D Barry
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

3.  Regulation of complement membrane attack complex formation in myocardial infarction.

Authors:  A Väkevä; P Laurila; S Meri
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

4.  Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55).

Authors:  J M Bergelson; J G Mohanty; R L Crowell; N F St John; D M Lublin; R W Finberg
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

5.  The alternative complement pathway regulates pathological angiogenesis in the retina.

Authors:  J Harry Sweigard; Ryoji Yanai; Philipp Gaissert; Magali Saint-Geniez; Keiko Kataoka; Aristomenis Thanos; Gregory L Stahl; John D Lambris; Kip M Connor
Journal:  FASEB J       Date:  2014-03-25       Impact factor: 5.191

6.  Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas.

Authors:  K Koretz; S Brüderlein; C Henne; P Möller
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.